International forskning

Clinical outcome data of chronic pain patients treated with cannabis-based oils and dried flower from the UK Medical Cannabis Registry

James Tait 1, Simon Erridge 1 2, Carl Holvey 2, Ross Coomber 2 3, Azfer Usmani 2 4, Mohammed Sajad 2 5, Jonathan Hoare 1 2, Shaheen Khan 2 6, Mark Weatherall 2 7, James J Rucker 2 8 9, Michael Platt 1 2, Mikael H Sodergren 1 2

  • 1Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK.
  • 2Department of Medicine, Sapphire Medical Clinics, London, UK.
  • 3Department of Trauma and Orthopaedics, St. George’s Hospital NHS Trust, London, UK.
  • 4Department of Anaesthesia, Dartford and Gravesham NHS Trust, Kent, UK.
  • 5Department of Anaesthesia, Dudley Group of Hospitals NHS Trust, West Midlands, UK.
  • 6Department of Palliative Medicine, Guy’s and St. Thomas’ NHS Foundation Trust, London, UK.
  • 7Department of Neurology, Buckinghamshire Healthcare NHS Trust, Amersham, UK.
  • 8Department of Psychological Medicine, King’s College London, London, UK.
  • 9Centre for Affective Disorders, South London & Maudsley NHS Foundation Trust, London, UK.


Background: The following study evaluated the clinical outcomes of patients enrolled in the UK Medical Cannabis Registry, who were treated with inhaled dried flower (Adven® EMT2, Curaleaf International, Guernsey), and sublingual/oral medium-chain triglyceride-based oils (Adven, Curaleaf International, Guernsey) for chronic pain.

Methods: In this cohort study, the primary outcomes were changes in validated patient reported outcome measures (PROMs) at 1, 3, and 6 months compared to baseline, and adverse event analysis. Statistical significance was defined as p < 0.050. Results: Three hundred and forty-eight (45.7%), 36 (4.7%), and 377 (49.5%) patients were treated with oils, dried flower, or both, respectively. Patients treated with oils or combination therapy recorded improvements within health-related quality of life, pain, and sleep-specific PROMs at 1, 3, and 6 months (p < 0.050). Patients treated with combination therapy recorded improvements in anxiety-specific PROMs at 1, 3, and 6 months (p < 0.050). 1,273 (167.3%) adverse events were recorded, with previously cannabis naïve users, ex-cannabis users, and females more likely to experience adverse events (p < 0.050). Conclusions: This study observed an association between initiation of CBMP treatment and improved outcomes for chronic pain patients. Prior cannabis use and gender were associated with adverse event incidence. Placebo-controlled trials are still necessary to establish the efficacy and safety of CBMPs for chronic pain.